Jordan's Hikma, Affected By 'Arab Spring,' To Resume Libya Sales
This article was originally published in PharmAsia News
Jordan's Hikma Pharmaceuticals said it plans to resume marketing its drugs in Libya by the end of the year, ending a hiatus brought about by political upheaval
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.